Histiocytoid Sweet's syndrome during combined therapy with BRAF and MEK inhibitors for metastatic melanoma

Melanoma Res. 2018 Jun;28(3):256-257. doi: 10.1097/CMR.0000000000000438.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Female
  • Humans
  • Imidazoles / administration & dosage
  • Imidazoles / adverse effects
  • MAP Kinase Kinase Kinases / antagonists & inhibitors*
  • Melanoma / drug therapy*
  • Melanoma / enzymology
  • Melanoma / pathology
  • Middle Aged
  • Oximes / administration & dosage
  • Oximes / adverse effects
  • Protein Kinase Inhibitors / adverse effects*
  • Protein Kinase Inhibitors / therapeutic use
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
  • Pyridones / administration & dosage
  • Pyridones / adverse effects
  • Pyrimidinones / administration & dosage
  • Pyrimidinones / adverse effects
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology
  • Sweet Syndrome / chemically induced*
  • Sweet Syndrome / pathology

Substances

  • Imidazoles
  • Oximes
  • Protein Kinase Inhibitors
  • Pyridones
  • Pyrimidinones
  • trametinib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • MAP Kinase Kinase Kinases
  • dabrafenib